Latest news with #ExactSciences
Yahoo
18 hours ago
- Business
- Yahoo
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024
The global multi cancer early detection market is set to grow from USD 1 billion in 2024 to USD 4.3 billion by 2033, driven by advancements in genomics, AI, and imaging. Increased awareness and preventive healthcare measures are boosting demand. Key players include GRAIL, Inc., Guardant Health, and Exact Sciences. Multi Cancer Early Detection Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Multi Cancer Early Detection Market and Forecasts 2025-2033" report has been added to offering. The global multi cancer early detection market size was valued at USD 1 billion in 2024 and is likely to reach USD 4.3 billion by 2033, expanding at a CAGR 16.9% during the forecast period. The multi cancer early detection market is experiencing significant growth as advancements in technology and changing healthcare paradigms evolve. Early detection of cancer can lead to improved treatment outcomes and potentially save lives, making this market increasingly important in the realm of healthcare. One of the primary drivers of the multi cancer early detection market is the rapid advancement of diagnostic technologies. Innovations in genomics, artificial intelligence, and imaging techniques are enhancing the accuracy and efficiency of cancer detection. These cutting-edge technologies allow for the identification of multiple cancer types simultaneously, which is crucial for timely intervention. Another key factor contributing to the market's expansion is the growing public awareness regarding the importance of early cancer detection. More individuals are prioritizing preventive healthcare measures, leading to increased screenings and tests. Health campaigns and education initiatives are empowering patients to take charge of their health, thereby stimulating demand for multi-cancer early detection solutions. Multi Cancer Early Detection Market Synopsis This new 2025 market report presents an in-depth assessment of the global multi cancer early detection market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global multi-cancer early detection market. The report also provides up-to-date historical market size data for the period 2020 - 2024 and an illustrative forecast to 2033 covering key market aspects like market value, share, analysis, and trends for the global multi cancer early detection market. The report provides a detailed analysis of the current industry situation and market requirements, highlighting facts about the market size, market share, revenue for global multi cancer early detection market segments, and a vivid forecast to 2033. It also provides a comprehensive analysis of the pricing landscape, policies and regulation, and reimbursement pattern by countries and regions. The report also offers analysis and information according to categories such as market segments, application, technology, geographies, companies and competitive landscape. The report also provides a detailed description of the porter's five forces analysis, PESTEL analysis, SWOT analysis, funding, merger and acquisitions, pipeline, growth drivers and challenges of the global multi cancer early detection market. The report concludes with the profiles of major market players in the global multi cancer early detection market. The key market players are evaluated on various parameters such as company overview, product landscape, recent developments in multi cancer early detection, funding & M&A, strategic outlook, challenges and risks of the global multi cancer early detection market. Multi Cancer Early Detection Market by Key Players GRAIL, Inc. (an Illumina Company) Guardant Health Exact Sciences Corporation Illumina, Inc. Freenome Holdings, Inc. Burning Rock Biotech Limited Foundation Medicine, Inc. AnchorDx Beijing Lyman Juntai International Medical Technology Development Co. Genecast Singlera Genomics Inc Thrive Earlier Detection (acquired by Exact Sciences Corporation) Key Features of the Report The global multi cancer early detection market provides granular level information about the market size, regional market share, historic market (2020-2024), and forecast (2025-2033). Annualized revenues and country level analysis for each market segment. Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. Detailed analysis of geographical landscape with country level analysis of major regions. The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies. The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market. The report tracks recent innovations, key developments, and start-up details that are actively working in the market. The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios. The report analyses the impact of the socio-political environment through SWOT analysis and competition through porter's five force analysis and PESTEL analysis Through study of the key business strategies and recommendations on future market approach. Comprehensive analysis of the competitive structure of the market. Demand side and supply side analysis of the market. Key Questions the Report Addresses How big is the global multi cancer early detection market? What is the current multi cancer early detection market size? What is the major driving factor for the multi cancer early detection market? Which factor is restraining the growth of the multi cancer early detection market? Who are the key players in the multi cancer early detection market? Which region has the biggest share in the multi cancer early detection market? Which is the fastest growing country in the multi cancer early detection market? Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1 Billion Forecasted Market Value (USD) by 2033 $4.3 Billion Compound Annual Growth Rate 16.9% Regions Covered Global Key Topics Covered: 1. Market Definition 2. Research and Methodology 3. Executive Summary 4. Global Multi Cancer Early Detection - Market Dynamics4.1 Growth Drivers4.2 Challengers4.3 Funding and Merger & Acquisitions 5. Global Multi Cancer Early Detection Market - Industry Analysis5.1 SWOT Analysis5.2 Porter's Analysis 6. Global Multi Cancer Early Detection (MCED) Market & Forecast 7. Global Multi Cancer Early Detection (MCED) Market Share & Forecast7.1 By Types7.2 By End Use7.3 By Region7.4 By Country 8. By Types - Global Multi Cancer Early Detection (MCED) Market & Forecast8.1 Gene Panel, IDT & Others8.2 Liquid Biopsy 9. By End Use - Global Multi Cancer Early Detection (MCED) Market & Forecast9.1 Hospitals9.2 Diagnostic Laboratories9.3 Others 10. By Region - Global Multi Cancer Early Detection (MCED) Market & Forecast10.1 North America10.2 Europe10.3 Asia Pacific10.4 Latin America10.5 Middle East & Africa 11. By Country - Global Multi Cancer Early Detection (MCED) Market & Forecast 12. Global Multi Cancer Early Detection Market - Key Players Profiles GRAIL, Inc. (an Illumina Company) Guardant Health Exact Sciences Corporation Illumina, Inc. Freenome Holdings, Inc. Burning Rock Biotech Limited FOUNDATION MEDICINE, INC. AnchorDx Beijing Lyman Juntai International Medical Technology Development Co. GENECAST Singlera Genomics Inc. Thrive Earlier Detection (acquired by Exact Sciences Corporation) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Multi Cancer Early Detection Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
18 hours ago
- Business
- Yahoo
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024
The global multi cancer early detection market is set to grow from USD 1 billion in 2024 to USD 4.3 billion by 2033, driven by advancements in genomics, AI, and imaging. Increased awareness and preventive healthcare measures are boosting demand. Key players include GRAIL, Inc., Guardant Health, and Exact Sciences. Multi Cancer Early Detection Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Multi Cancer Early Detection Market and Forecasts 2025-2033" report has been added to offering. The global multi cancer early detection market size was valued at USD 1 billion in 2024 and is likely to reach USD 4.3 billion by 2033, expanding at a CAGR 16.9% during the forecast period. The multi cancer early detection market is experiencing significant growth as advancements in technology and changing healthcare paradigms evolve. Early detection of cancer can lead to improved treatment outcomes and potentially save lives, making this market increasingly important in the realm of healthcare. One of the primary drivers of the multi cancer early detection market is the rapid advancement of diagnostic technologies. Innovations in genomics, artificial intelligence, and imaging techniques are enhancing the accuracy and efficiency of cancer detection. These cutting-edge technologies allow for the identification of multiple cancer types simultaneously, which is crucial for timely intervention. Another key factor contributing to the market's expansion is the growing public awareness regarding the importance of early cancer detection. More individuals are prioritizing preventive healthcare measures, leading to increased screenings and tests. Health campaigns and education initiatives are empowering patients to take charge of their health, thereby stimulating demand for multi-cancer early detection solutions. Multi Cancer Early Detection Market Synopsis This new 2025 market report presents an in-depth assessment of the global multi cancer early detection market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global multi-cancer early detection market. The report also provides up-to-date historical market size data for the period 2020 - 2024 and an illustrative forecast to 2033 covering key market aspects like market value, share, analysis, and trends for the global multi cancer early detection market. The report provides a detailed analysis of the current industry situation and market requirements, highlighting facts about the market size, market share, revenue for global multi cancer early detection market segments, and a vivid forecast to 2033. It also provides a comprehensive analysis of the pricing landscape, policies and regulation, and reimbursement pattern by countries and regions. The report also offers analysis and information according to categories such as market segments, application, technology, geographies, companies and competitive landscape. The report also provides a detailed description of the porter's five forces analysis, PESTEL analysis, SWOT analysis, funding, merger and acquisitions, pipeline, growth drivers and challenges of the global multi cancer early detection market. The report concludes with the profiles of major market players in the global multi cancer early detection market. The key market players are evaluated on various parameters such as company overview, product landscape, recent developments in multi cancer early detection, funding & M&A, strategic outlook, challenges and risks of the global multi cancer early detection market. Multi Cancer Early Detection Market by Key Players GRAIL, Inc. (an Illumina Company) Guardant Health Exact Sciences Corporation Illumina, Inc. Freenome Holdings, Inc. Burning Rock Biotech Limited Foundation Medicine, Inc. AnchorDx Beijing Lyman Juntai International Medical Technology Development Co. Genecast Singlera Genomics Inc Thrive Earlier Detection (acquired by Exact Sciences Corporation) Key Features of the Report The global multi cancer early detection market provides granular level information about the market size, regional market share, historic market (2020-2024), and forecast (2025-2033). Annualized revenues and country level analysis for each market segment. Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. Detailed analysis of geographical landscape with country level analysis of major regions. The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies. The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market. The report tracks recent innovations, key developments, and start-up details that are actively working in the market. The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios. The report analyses the impact of the socio-political environment through SWOT analysis and competition through porter's five force analysis and PESTEL analysis Through study of the key business strategies and recommendations on future market approach. Comprehensive analysis of the competitive structure of the market. Demand side and supply side analysis of the market. Key Questions the Report Addresses How big is the global multi cancer early detection market? What is the current multi cancer early detection market size? What is the major driving factor for the multi cancer early detection market? Which factor is restraining the growth of the multi cancer early detection market? Who are the key players in the multi cancer early detection market? Which region has the biggest share in the multi cancer early detection market? Which is the fastest growing country in the multi cancer early detection market? Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1 Billion Forecasted Market Value (USD) by 2033 $4.3 Billion Compound Annual Growth Rate 16.9% Regions Covered Global Key Topics Covered: 1. Market Definition 2. Research and Methodology 3. Executive Summary 4. Global Multi Cancer Early Detection - Market Dynamics4.1 Growth Drivers4.2 Challengers4.3 Funding and Merger & Acquisitions 5. Global Multi Cancer Early Detection Market - Industry Analysis5.1 SWOT Analysis5.2 Porter's Analysis 6. Global Multi Cancer Early Detection (MCED) Market & Forecast 7. Global Multi Cancer Early Detection (MCED) Market Share & Forecast7.1 By Types7.2 By End Use7.3 By Region7.4 By Country 8. By Types - Global Multi Cancer Early Detection (MCED) Market & Forecast8.1 Gene Panel, IDT & Others8.2 Liquid Biopsy 9. By End Use - Global Multi Cancer Early Detection (MCED) Market & Forecast9.1 Hospitals9.2 Diagnostic Laboratories9.3 Others 10. By Region - Global Multi Cancer Early Detection (MCED) Market & Forecast10.1 North America10.2 Europe10.3 Asia Pacific10.4 Latin America10.5 Middle East & Africa 11. By Country - Global Multi Cancer Early Detection (MCED) Market & Forecast 12. Global Multi Cancer Early Detection Market - Key Players Profiles GRAIL, Inc. (an Illumina Company) Guardant Health Exact Sciences Corporation Illumina, Inc. Freenome Holdings, Inc. Burning Rock Biotech Limited FOUNDATION MEDICINE, INC. AnchorDx Beijing Lyman Juntai International Medical Technology Development Co. GENECAST Singlera Genomics Inc. Thrive Earlier Detection (acquired by Exact Sciences Corporation) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Multi Cancer Early Detection Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Business Insider
3 days ago
- Business
- Business Insider
Cathie Wood Makes a $69M Bet on Exact Sciences; Sells Palantir, Roblox, and DraftKings
Cathie Wood 's ARK Invest ETFs (exchange-traded funds) made a $69 million bet on Exact Sciences (EXAS) on August 7, marking the largest purchase of the day. The move aligns with Wood's bullish outlook on the biotechnology sector. ARK Invest funds also acquired shares of Airbnb (ABNB), buying 179,197 shares valued at about $21.50 million. Additionally, Wood continued buying shares of CRISPR Therapeutics (CRSP), adding about $3.49 million worth of its stock. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. On the other hand, the largest sale trade for the day was 1,419,766 shares of Guardant Health (GH) for a huge $71.15 million. Wood also made a surprising sale of 155,217 shares of the online betting platform DraftKings (DKNG), totaling $7.01 million. Moreover, ARK funds sold 38,880 shares of Palantir Technologies (PLTR), amounting to roughly $7.08 million. Wood Pours Millions into Exact Sciences Exact Sciences made its debut in the ARK Invest funds yesterday. The ARK Innovation ETF (ARKK) purchased 1,394,210 shares of Exact Sciences, and the ARK Genomic Revolution ETF (ARKG) bought another 216,512 shares. EXAS stock plunged nearly 8%, marking its 52-week low of $38.81 on August 7. On Wednesday, Exact Sciences reported better-than-expected Q2 results, with a loss narrowing to $0.01 per share. Revenue came in at $811 million, also beating the consensus estimate. Nonetheless, analysts lowered their price target on EXAS stock because they were disappointed with its blood-based colorectal cancer (CRC) test data, which led to the sharp stock price decline. Wood appears to have leveraged the dip in EXAS shares as the company has addressed the issue by signing a deal with competitor Freenome to get access to their blood-based CRC test and pipeline, with FDA approval expected in 2026. Is EXAS Stock a Buy, Hold, or Sell? On TipRanks, EXAS stock has a Strong Buy consensus rating based on 10 Buys and two Hold ratings. The average Exact Sciences price target of $65.75 implies 52.3% upside potential from current levels. Year-to-date, EXAS stock has lost 23.2%.
Yahoo
5 days ago
- Business
- Yahoo
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents. Revenues increased to $811.085 million, beating the consensus of $774.34 million. Sales jumped 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 margin was 69%, and adjusted gross margin was 72%. In addition, Exact Sciences shared initial results from an internal version of its colorectal cancer (CRC) blood test, showing sensitivities of 73% for CRC and 14% for APL at 90% specificity. Internal testing and evaluation of the assay are ongoing. Outlook Exact Sciences raised its fiscal 2025 sales guidance from $3.07 billion-3.12 billion to $3.13 billion-$3.17 billion versus the consensus of $3.099 billion. The guidance includes a Screening segment sales forecast of $2.44 billion-$2.47 billion, compared to previous guidance of $2.39 billion-$2.43 billion. Precision Oncology sales are expected to be $690 million-$700 million, compared to prior guidance of $680 million-$695 million. The company expects 2025 adjusted EBITDA of $455 million-$475 million, up from previous guidance of $425 million-$455 million. M&A Deal Exact Sciences on Thursday agreed to acquire exclusive rights in the United States to current and future versions of Freenome's blood-based, single-indication colorectal cancer (CRC) screening tests. View more earnings on EXAS Complete findings from the prospective PREEMPT study were recently published in JAMA. Results show Freenome's first version test achieved sensitivities of 81% for CRC and 14% for advanced precancerous lesions (APL) at specificity of 90%. Freenome recently submitted the last module of the premarket application to the FDA. Freenome then plans to submit a supplement to the FDA for its next-generation test once final clinical validation data are available. Analyst Reaction William Blair writes that investors are most focused on acquisition of the exclusive rights to Freenome's current and future blood-based colorectal cancer (CRC) screening tests. The announcement comes as the company's blood CRC test did not meet expectations in the pivotal trial. Analyst Andrew Brackmann notes that shares are trading lower, representing an opportunity to build or add to positions. William Blair notes that the Freenome deal helps the company move faster in making money from these tests, reduces the threat from competitors, and eases investor concerns that blood-based CRC tests could slow down growth in its screening business. It strengthens the company's position as the top player in noninvasive CRC screening. William also expects the numbers to improve later this year and into 2026. William Blair reiterated the Outperform rating. Barclays maintained its Overweight rating but adjusted its price forecast downward from $65 to $55. Similarly, RBC Capital kept its Sector Perform rating for Exact Sciences, reducing its price forecast from $54 to $46. Finally, UBS reiterated its Neutral stance on the company, lowering its price forecast from $61 to $53. Price Action: EXAS stock is trading lower by 12.3% to $41.13 at last check Thursday. Read Next:Photo by Faces Portrait via Shutterstock Latest Ratings for EXAS Date Firm Action From To Feb 2022 Wells Fargo Maintains Equal-Weight Feb 2022 Citigroup Maintains Neutral Feb 2022 Raymond James Maintains Outperform View More Analyst Ratings for EXAS View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? EXACT SCIENCES (EXAS): Free Stock Analysis Report This article Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Exact Sciences to acquire US rights for Freenome's blood-based CRC test
Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact Sciences plans to accelerate the market adoption of the CRC blood test by leveraging its commercial infrastructure. Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November. Freenome is set to receive up to an additional $700m, contingent upon reaching specific milestones related to its CRC screening tests. These milestones include a $100m payment upon receiving first-line approval from the Food and Drug Administration (FDA) for their inaugural test and another $100m for the approval of a subsequent, next-generation test that meets or exceeds certain performance criteria, such as a minimum of 19% advanced precancerous lesions (APL) sensitivity and 83% overall CRC sensitivity. However, should the performance fall below these benchmarks, the payment would be adjusted accordingly. Furthermore, Freenome could earn $500m if its test is classified as a first-line A or B test in the US Preventive Services Taskforce (USPSTF) guidelines or if it achieves certain payer-contracted coverage requirements. Again, a decreased payment is applicable if the test is included in the USPSTF guidelines as a second-line A or B test. Freenome could be entitled to obtain royalties that vary between 0% and 10%, depending on the profitability of the test, while also adhering to standard provisions for royalty stacking. However, if specific conditions are not fulfilled, Exact Sciences reserves the right to end the agreement. Exact Sciences noted that it is committed to investing $20m annually over three years in joint research and development to further utilise the technology. Freenome retains rights to its CRC blood test when combined with other cancer screening tests. The license agreement also includes a senior convertible note purchase by Exact Sciences, amounting to $50m, with a coupon rate of 5% due in 2030. Freenome's PREEMPT CRC Study, which involved nearly 49,000 adults at average risk, demonstrated the CRC test's ability to identify 81.1% of CRC, including 63.5% at stage one, and 13.7% of APL, with a specificity of 90.4%. Freenome is also working on an 'improved version' of the test, which has shown enhanced performance in detection rates, and plans to submit a supplemental premarket approval application to the FDA once final clinical validation data are available. In a recent development, Exact Sciences expanded its collaboration with private insurer Humana to make the Cologuard Plus test available to eligible Humana Medicare Advantage members as an in-network service across the US. "Exact Sciences to acquire US rights for Freenome's blood-based CRC test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
